Pfizer has initiated a pivotal Phase 3 study for its 25-valent pediatric pneumococcal vaccine (25vPnC) after Phase 2 data showed a 15-fold increase in immune response against serotype 3.
Pfizer has reported its first-quarter 2026 earnings, exceeding market expectations with $14.5 billion in revenue. The company reaffirmed its full-year guidance, bolstered by a 22% operational growth in launched and acquired products.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
Topline results from the Phase 3 VALOR study demonstrate that the Lyme disease vaccine candidate (PF-07307405) is safe, well-tolerated, and effective for adults and children.
Pfizer’s landmark Phase 3 TALAPRO-3 trial confirms that the Talzenna Xtandi rPFS mCSPC combination markedly exceeds its pre-specified efficacy target — advancing PARP inhibition earlier into the prostate cancer treatment course than ever before proven in a randomised study.
Atirmociclib Phase 2 data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically [Read More…]
Pfizer’s investigational trispecific antibody, tilrekimig, met its primary endpoint in a Phase 2 study for atopic dermatitis, showing significant skin clearance and a favorable safety profile.
The FDA has approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as the first perioperative treatment regimen to significantly improve survival in cisplatin-ineligible patients with muscle-invasive bladder cancer. Based on pivotal Phase 3 EV-303 trial data, the combination demonstrated a 60% reduction in recurrence or death risk and a 50% reduction in mortality risk compared to surgery alone.
Pfizer announced FDA full approval of BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for treating adults with BRAF V600E-mutant metastatic colorectal cancer. The landmark approval is backed by Phase 3 BREAKWATER trial data demonstrating a 51% reduction in mortality risk and 47% reduction in disease progression risk compared to standard chemotherapy.
Pfizer announced positive progression-free survival results from BREAKWATER trial Cohort 3, showing BRAFTOVI combined with cetuximab and FOLFIRI achieves statistically significant and clinically meaningful progression-free survival improvement compared to chemotherapy alone in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.
